Unterehmen auf Watchlist setzen
Applied Therapeutics
ISIN: US03828A1016
WKN: A2PHHB
Über
Unternehmensprofil
Tipp: Investor-Alerts aktivieren
Lassen Sie sich bei neuen Publikationen informieren
Tipp: AI-Factsheet

Corporate News meets AI! 
Analyse der Inhalte und Zusammenfassung

Applied Therapeutics · ISIN: US03828A1016 · Business Wire (ID: 20241218460639)
18 Dezember 2024 06:02PM

Rosen Law Firm Urges Applied Therapeutics, Inc. (NASDAQ: APLT) Investors with Losses in Excess of $100K to Contact the Firm for Information About Their Rights


Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of Applied Therapeutics, Inc. (NASDAQ: APLT) securities between January 3, 2024 and December 2, 2024, both dates inclusive (the “Class Period”). Applied Therapeutics is a clinical-stage biopharmaceutical company.

For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653.

The Allegations: Rosen Law Firm is Investigating the Allegations that Applied Therapeutics (NASDAQ: APLT) Misled Investors Regarding its Business Operations.

According to the lawsuit, statements made during the class period were false and/or materially misleading because they concealed and misrepresented the clinical trial protocols and procedures that Applied Therapeutics had in place. Therefore, defendants provided investors with the false impression that protocol and good clinical practices were being properly followed. In truth, the lawsuit alleges that Applied Therapeutics was not adhering to trial protocol and good clinical practices which, in turn, created an exceedingly severe risk that the trial data would be rejected by the FDA in the context of a New Drug Application. When the true details entered the market, the lawsuit claims that investors suffered damages.

What Now: You may be eligible to participate in the class action against Applied Therapeutics. Shareholders who want to serve as lead plaintiff for the class must file their motions with the court by February 18, 2025. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

About Rosen Law Firm: Some law firms issuing releases about this matter do not actually litigate securities class actions. Rosen Law Firm does. Rosen Law Firm is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses, improving corporate governance structures, and holding company executives accountable for their wrongdoing. Since its inception, Rosen Law Firm has obtained over $1 billion for shareholders.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
case@rosenlegal.com
www.rosenlegal.com

Visuelle Wertentwicklung / Kursverlauf · Applied Therapeutics
Smarte Analyse- und Recherchewerkzeuge finden Sie hier.
This publication was provided by our content partner Business Wire
BusinessWire
via BusinessWire - Newsfeed
BusinessWire ©2024
BusinessWire
Kontakt:
101 California Street, 20th Floor San Francisco, CA, 94111 United States
+1.415.986.4422